A subgroup analysis of perioperative pembrolizumab in clinical stage II non-small-cell lung cancer from the randomized keynote-671 study - PubMed
5 hours ago
- #pembrolizumab
- #perioperative therapy
- #non-small-cell lung cancer
- Subgroup analysis of perioperative pembrolizumab in clinical stage II non-small-cell lung cancer (NSCLC) from the KEYNOTE-671 study.
- Pembrolizumab plus neoadjuvant chemotherapy improved outcomes vs. chemotherapy alone in resectable NSCLC.
- Study included 239 participants with stage II disease (118 pembrolizumab + chemo, 121 chemo only).
- Pembrolizumab arm showed higher R0 resection rates (94.9% vs. 86.4%), improved event-free survival (HR 0.50), and overall survival (HR 0.69).
- Major pathological response and pathological complete response rates were significantly higher in the pembrolizumab arm.
- Grade 3-4 treatment-related adverse events occurred in 50.0% (pembrolizumab + chemo) vs. 40.5% (chemo only), with no treatment-related deaths.
- Results support perioperative pembrolizumab regimen for stage II NSCLC with manageable safety.